consumer_protection · food_and_nutrition · agriculture · HHS-FDA
Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)
Food and Drug Administration · FOR-FD-24-004
Award Range
$250K – $250K
Expected Awards
1
Deadline
TBD
GRANTQUICK SUMMARYPlain-English Overview
Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required). Food and Drug Administration. The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to... $250,000-$250,000 per award; ~1 awards expected.
Who Should Apply
Other Native American Tribal Organizations, Special district governments, For-profit organizations, Unrestricted (any eligible entity), Independent school districts (+11 more)
Who Should NOT Apply
Few restrictions — most eligible entities can apply
Key Requirements (Plain English)
- •Applicant organizations may submit more than one application, provided that each application is scientifically distinct
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: Very high — extremely limited awards available
What This Grant Funds
The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.
Who Can Apply
Eligible Applicant Types
Funding Details
- Minimum Award
- $250K
- Maximum Award
- $250K
- Expected Number of Awards
- 1
- Cost Sharing Required?
- No
- Funding Instrument
- cooperative_agreement
Key Dates
Agency Contact
Terrin Brown Grantor 2403387494
terrin.brown@fda.hhs.govReady to apply?
View the full NOFO and submit your application on Grants.gov